Updated UK Recommendations for HER2 assessment in breast cancer

Human epidermal growth factor receptor 2 (HER2) overexpression is present in approximately 15% of early invasive breast cancers, and is an important predictive and prognostic marker. The substantial benefits achieved with anti-HER2 targeted therapies in patients with HER2-positive breast cancer have...

Descripción completa

Detalles Bibliográficos
Autores principales: Rakha, Emad A, Pinder, Sarah E, Bartlett, John M S, Ibrahim, Merdol, Starczynski, Jane, Carder, Pauline J, Provenzano, Elena, Hanby, Andrew, Hales, Sally, Lee, Andrew H S, Ellis, Ian O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Best Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316916/
https://www.ncbi.nlm.nih.gov/pubmed/25488926
http://dx.doi.org/10.1136/jclinpath-2014-202571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316916/
https://www.ncbi.nlm.nih.gov/pubmed/25488926
http://dx.doi.org/10.1136/jclinpath-2014-202571

Ejemplares similares